NCT05828472View on ClinicalTrials.gov

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

MY008211A tablets

MY008211A tablets, low/moderate/high dose orally, for 7 days

DRUG

MY008211A tablets matched placebo

MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days

Trial Locations (1)

410011

The Third Hospital of Changsha, Changsha

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY